Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent, data shows
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
List view / Grid view
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
Bayer has signed a collaboration and services agreement with CureVac for the development of CVnCoV, a COVID-19 vaccine currently in late-stage trials.
Researchers evaluate the various microbiological monitoring (MM) methods employed inside a laminar airflow or safety cabinet in hospital pharmacies.
Moderna's COVID-19 vaccine has been approved in the EU with a conditional marketing authorisation by the European Commission.
Scientists have used inert oils to control evaporative solvent loss to grow small crystals from nanoscale encapsulated droplets.
Researchers say that their novel way to produce synthetic insulin could also be used to create at least eight other drugs.
The new pathway developed by NICE for medicines to go from clinical trials to NHS patients is now in action.
The study will determine if the combination of BRII-196 and BRII-198, two investigational antibodies for SARS-CoV-2, can prevent disease progression.
Growth of the global protein crystallisation and crystallography market is attributed to increasing interest in biologics, more investment and advancing technologies.
Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
The new COVID-19 test, called RTF-EXPAR, was able to accurately detect the presence of SARS-CoV-2 viral RNA in under five minutes.
Researchers have shown that microbial surface recovery using contact plates was superior on vinyl than stainless steel.
Ebanga was approved based on its ability to reduce 28-day mortality in patients with confirmed Ebolavirus infection.
The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease.
Phase III trial data suggests the mRNA-1273 vaccine is safe and highly effective at preventing COVID-19 in adults.